Spondyloarthritis

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.

Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."

The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.

A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.

Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.

Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.

Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

Study drug also recently showed promise in treating psoriatic arthritis.

The safety profile is consistent with previous studies of the ixekizumab.

Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.

The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.

The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.

The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.

Doses of secukinumab are clinically safe and beneficial for long-term treatment of psoriatic arthritis.

Rheumatology patients are more susceptible to infections, making self-quarantining extremely important for this population.

Patients with psoriatic arthritis are not at an increased risk of cancer, however.